Evidence map›Paper›PMID 40346484›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

The MYC/TXNIP axis mediates NCL-Suppressed CD8

Dan Xiao, Tanxiu Chen, Xinlin Yu, Ying Song, Yigang Liu, Wei Yan

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dan Xiao *Department of Thoracic Oncology, Jiangxi Cancer Hospital&Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, No. 519 Beijing East Road, Nanchang, 330029, Jiangxi, China.
Tanxiu Chen *Jiangxi Academy of Clinical Medical Sciences, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China.
Xinlin YuDepartment of Medical Laboratory, Jiangxi Cancer Hospital&Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, No. 519 Beijing East Road, 330029, Nanchang, China.
Ying SongDepartment of Medical Laboratory, Jiangxi Cancer Hospital&Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, No. 519 Beijing East Road, 330029, Nanchang, China.
Yigang LiuDepartment of Ultrasound Medicine, Jiangxi Cancer Hospital&Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, No. 519 Beijing East Road, Nanchang, 330029, Jiangxi, China. liuyigang1985@163.com.
Wei YanDepartment of Thoracic Oncology, Jiangxi Cancer Hospital&Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, No. 519 Beijing East Road, Nanchang, 330029, Jiangxi, China. yanwei19911013@163.com.

Funding

Jiangxi Provincial Health and Health Commission Science and Technology Plan Project 202510022Natural Science Foundation of Jiangxi province 20242BAB20254Science and Technology Research Project of Jiangxi Provincial Department of Education GJJ2403615the Open Research Fund of Jiangxi Cancer Hospital & Institute KFJJ2023YB15
6 · The paper itself

Abstract

backgroundLung adenocarcinoma is a deadly malignancy with immune evasion playing a key role in tumor progression. Glucose metabolism is crucial for T cell function, and the nucleolar protein NCL may influence T cell glucose metabolism. This study aims to investigate NCL's role in T cell glucose metabolism and immune evasion by lung adenocarcinoma cells.

methodsUtilizing single-cell RNA sequencing (scRNA-seq) data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA), we analyzed cell clustering, annotation, and prognosis. In vitro experiments involved manipulating NCL expression in CD8

resultsNCL was associated with T cell dysfunction and glucose metabolism. NCL silencing enhanced CD8

conclusionsNCL overexpression suppresses CD8

Indexed as

Adenocarcinoma of LungCD8-Positive T-LymphocytesLung NeoplasmsProto-Oncogene Proteins c-mycAnimalsCarrier ProteinsCell Line, TumorGene Expression Regulation, NeoplasticGlucoseHumansMiceCarrier ProteinsGlucoseMYC protein, humanProto-Oncogene Proteins c-mycTXNIP protein, humanCD8+ T cellsGlucose metabolismImmune escapeLung adenocarcinomaMYCNCL

Identifiers

PMID40346484
PMCPMC12063364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.